



## Pliant Therapeutics to Participate in Upcoming Investor Conferences

August 30, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant's senior management will participate in the following September investor conferences:

- **Citi's 17th Annual BioPharma Conference** on September 6 – 7, 2022 at the Four Seasons Hotel, Boston, Massachusetts
- **H.C. Wainwright 24th Annual Global Investment Conference** virtually on September 12 – 14, 2022. Dr Coulie's pre-recorded fireside chat will be available on Monday, September 12, 2022, at 7:00 a.m. ET

Interested parties can access the H.C. Wainwright fireside chat from the Investor Relations' Events & Presentation page of Pliant's website at <https://ir.pliantx.com/news-and-events/events-and-presentations> with an audio archive available for 30 days from the time it is made available.

### About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of  $\alpha\text{v}\beta 6$  and  $\alpha\text{v}\beta 1$  integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in PSC. Pliant is currently conducting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of  $\alpha\text{v}\beta 1$  for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, [visit www.pliantx.com](https://www.pliantx.com) and follow us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

### Investor and Media Contact:

Christopher Keenan  
Vice President, Investor Relations and Corporate Communications  
Pliant Therapeutics, Inc.  
[ir@pliantrx.com](mailto:ir@pliantrx.com)